SNGXSOLIGENIX, INC.同业对比
SOLIGENIX, INC. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNGX本股 | $8M#8 | — | 1.2x#8 | 65.8x#7 | -85.8%#7 | -33.7%#14 | -9923.2%#8 | -167.0%#9 | — | 5#1 | -87.0%#15 | — |
| APRE | $9M#1 | — | 0.2x#1 | — | — | 2.8%#11 | — | -32.8%#5 | — | — | -50.0%#4 | — |
| ALZN | $9M#2 | — | 1.5x#10 | — | — | -94.3%#15 | — | -151.2%#8 | — | — | -30.0%#3 | — |
| ENSC | $9M#4 | — | — | 1.7x#4 | -2.8%#5 | -27.4%#13 | -202.1%#3 | — | — | — | -78.8%#13 | — |
| BFRG | $9M#5 | — | 1.2x#9 | 74.9x#8 | — | 7.1%#10 | -5652.4%#7 | -93.0%#6 | -5287.3%#4 | — | -66.6%#8 | — |
| CNSP | $9M#6 | — | 0.5x#2 | — | — | -7.6%#12 | — | -0.1%#3 | — | — | -24.5%#1 | — |
| XCUR | $9M#3 | — | 9.0x#13 | — | -100.0%#8 | 49.0%#5 | — | -506.2%#13 | — | — | -64.6%#7 | — |
| TRAW | $8M#7 | — | 0.7x#5 | 2.9x#5 | 1134.5%#1 | 105.5%#2 | -640.7%#5 | 79.2%#2 | — | — | -75.7%#12 | — |
| IMNN | $8M#9 | — | — | — | — | — | — | — | — | — | -74.4%#11 | — |
| ACXP | $7M#10 | — | 0.9x#7 | — | — | 43.5%#8 | — | -97.7%#7 | — | — | -66.6%#9 | — |
| BOLT | $7M#11 | — | 0.6x#3 | 0.9x#3 | 0.1%#4 | 47.1%#6 | -469.3%#4 | -264.1%#11 | — | — | -28.8%#2 | — |
| SYBX | $7M#12 | — | 0.6x#4 | — | -100.0%#8 | 95.7%#3 | — | -8.4%#4 | — | — | -63.8%#6 | — |
| ENVB | $7M#13 | — | 0.8x#6 | 0.2x#1 | -7.2%#6 | 26.0%#9 | -22.0%#1 | 149.7%#1 | -100.4%#1 | 3#2 | -86.4%#14 | — |
| ERNA | $6M#14 | 0.1x#1 | 2.0x#11 | 11.0x#6 | 755.9%#2 | 68.4%#4 | -1601.2%#6 | -440.1%#12 | -1016.2%#3 | — | -87.4%#16 | — |
| PCSA | $5M#15 | 2.9x#2 | — | — | — | 214.5%#1 | — | — | — | — | -62.5%#5 | 0.8%#1 |
| PULM | $5M#16 | — | 2.0x#12 | 0.7x#2 | 7.0%#3 | 46.0%#7 | -66.2%#2 | -201.9%#10 | -235.7%#2 | — | -71.6%#10 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议